Peel Hunt Reiterates Buy Rating for Shield Therapeutics PLC (STX)

Shield Therapeutics PLC (LON:STX)‘s stock had its “buy” rating restated by equities researchers at Peel Hunt in a report issued on Tuesday. They currently have a GBX 220 ($2.90) price target on the stock. Peel Hunt’s price objective suggests a potential upside of 39.68% from the stock’s current price.

A number of other analysts have also recently issued reports on STX. Liberum Capital reiterated a “buy” rating and set a GBX 245 ($3.23) target price on shares of Shield Therapeutics PLC in a report on Wednesday, September 6th. FinnCap initiated coverage on Shield Therapeutics PLC in a report on Thursday, September 7th. They set a “buy” rating and a GBX 270 ($3.56) target price for the company.

Shares of Shield Therapeutics PLC (LON STX) opened at 157.50 on Tuesday. Shield Therapeutics PLC has a 12 month low of GBX 155.00 and a 12 month high of GBX 175.00. The stock’s 50 day moving average is GBX 157.50 and its 200 day moving average is GBX 160.68. The firm’s market cap is GBX 183.37 million.

ILLEGAL ACTIVITY NOTICE: “Peel Hunt Reiterates Buy Rating for Shield Therapeutics PLC (STX)” was published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/10/31/peel-hunt-reiterates-buy-rating-for-shield-therapeutics-plc-stx.html.

Shield Therapeutics PLC Company Profile

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on the development and commercialization of secondary care-focused pharmaceuticals. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease. Its advanced pipeline asset is PT20, a novel therapy that has completed its first pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease.

What are top analysts saying about Shield Therapeutics PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Shield Therapeutics PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit